Protein Kinase Inhibitors: all 15,278 studies that test it

Page 47 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis VulgarisCompletedNCT02106195Phase 2Results posted
• Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureActive, not recruitingNCT02105766Phase 2Results posted
• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has SpreadCompletedNCT02102490Phase 2Results posted
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerCompletedNCT02101788Phase 2/3Results posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and AdultsCompletedNCT02101736Phase 2Results posted
• Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3Results posted
• PD 0332991 and Cetuximab in Patients With Incurable SCCHNCompletedNCT02101034Phase 1/2Results posted
• Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02101021Phase 3Results posted
• ME-344 Given in Combination With Hycamtin® in Patients With Solid TumorsTerminatedNCT02100007Phase 1/2Results posted
• Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT02098538Phase 2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in VolunteersCompletedNCT02096679Phase 1Results posted
• MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1CompletedNCT02096471Phase 2Results posted
• Novartis Everolimus TransitionCompletedNCT02096107Phase 4Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticCompletedNCT02094872Phase 2Results posted
• A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02094573Phase 2Results posted
• Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive TumoursCompletedNCT02094261Phase 2Results posted
• Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-StudyTerminatedNCT02092961Phase 2Results posted
• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisCompletedNCT02092467Phase 4Results posted
• Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid LeukemiaCompletedNCT02092324Phase 2Results posted
• A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)TerminatedNCT02091752Phase 2Results posted
• Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) PatientsCompletedNCT02091531Phase 2Results posted
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
• MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard TherapyTerminatedNCT02089230Phase 1/2Results posted
• Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung CancerTerminatedNCT02087241Phase 2Results posted
• A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung CancerTerminatedNCT02087176Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaCompletedNCT02083354Phase 2Results posted
• A Study of Regorafenib in Advanced Pancreatic Cancer PatientsCompletedNCT02080260Phase 2Results posted
• Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT02079740Phase 1/2Results posted
• Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02077192Phase 3Results posted
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
• First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular DegenerationCompletedNCT02076919Phase 1Results posted
• A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076412Phase 3Results posted
• A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076399Phase 3Results posted
• A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedNCT02075840Phase 3Results posted
• Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
• Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerCompletedNCT02069093Phase 2Results posted
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerCompletedNCT02066532Phase 1/2Results posted
• A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX AloneCompletedNCT02066389Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive FibromatosisCompletedNCT02066181Phase 3Results posted
• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2Results posted
• To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy SubjectsCompletedNCT02063230Phase 1Results posted
• SRL (Sirolimus) WithdrawalCompletedNCT02062944Not applicableResults posted
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT02060370Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerTerminatedNCT02059265Phase 2Results posted
• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerCompletedNCT02059213Phase 2Results posted
• A Study of LY2835219 in Healthy ParticipantsCompletedNCT02059148Phase 1Results posted
• To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male VolunteersCompletedNCT02056392Phase 1Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line ChemotherapyCompletedNCT02053376Phase 2Results posted
• A Study of TAS-120 in Patients With Advanced Solid TumorsCompletedNCT02052778Phase 1/2Results posted
• Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue SarcomaCompletedNCT02050919Phase 2Results posted
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced MelanomaTerminatedNCT02050321Phase 2Results posted
• A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07CompletedNCT02049515Phase 3Results posted
• Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
• An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisCompletedNCT02049138Phase 2Results posted
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT02048813Phase 3Results posted
• Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced AngiosarcomaCompletedNCT02048722Phase 2Results posted
• SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma SubtypesCompletedNCT02048371Phase 2Results posted
• A Phase II Study of Dacomitinib in Progressive Brain MetastasesTerminatedNCT02047747Phase 2Results posted
• Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionTerminatedNCT02044822Phase 2Results posted
• Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT02044380Phase 3Results posted
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
• Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in JapanCompletedNCT02042014Phase 3Results posted
• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaCompletedNCT02041429Phase 1/2Results posted
• LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02040870Phase 1/2Results posted
• Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results posted
• Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainCompletedNCT02039947Phase 2Results posted
• (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD PositiveCompletedNCT02039726Phase 3Results posted
• Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)CompletedNCT02038647Phase 2Results posted
• Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.CompletedNCT02038036Phase 3Results posted
• BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane TxCompletedNCT02038010Phase 1Results posted
• Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaTerminatedNCT02036476Phase 2Results posted
• Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 2Results posted
• Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on MetforminCompletedNCT02033876Phase 2Results posted
• Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTerminatedNCT02031536Phase 2Results posted
• ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaActive, not recruitingNCT02029443Phase 1/2Results posted
• Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results posted
• Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02024087Phase 1/2Results posted
• Everolimus With and Without Temozolomide in Adult Low Grade GliomaTerminatedNCT02023905Phase 2Results posted
• Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal AdenocarcinomaCompletedNCT02023333Phase 2Results posted
• Sorafenib for Hepatopulmonary SyndromeTerminatedNCT02021929Phase 2Results posted
• Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid TumoursCompletedNCT02020577Phase 1Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)CompletedNCT02018861Phase 1/2Results posted
• Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.CompletedNCT02017860Phase 2Results posted
• Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal TumorsCompletedNCT02015065Phase 2Results posted
• Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02014558Phase 1/2Results posted
• A Study of LY2835219 in Japanese Participants With Advanced CancerCompletedNCT02014129Phase 1Results posted
• A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their BodyTerminatedNCT02014116Phase 1Results posted
• SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCDTerminatedNCT02013375Phase 2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to ChemotherapyCompletedNCT02013206Phase 2Results posted
• A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaCompletedNCT02011945Phase 1Results posted
• Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder CancerCompletedNCT02009332Phase 1/2Results posted
• SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)CompletedNCT02008877Phase 1/2Results posted
• A Study of Galunisertib in Participants With Myelodysplastic SyndromesCompletedNCT02008318Phase 2/3Results posted
• A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)CompletedNCT02004522Phase 3Results posted

← Protein Kinase Inhibitors overview